North America Breast Cancer Screening Test Market Size, Share, and COVID-19 Impact Analysis, By Diagnostics Test Type (Blood Marker Test, Imaging Test, Genetic Test, and Immunohistochemistry Test), By End-User (Hospitals, Diagnostic Centres, Cancer Institutes, and Research Laboratories), and North America Breast Cancer Screening Test Market Insights, Industry Trend, Forecasts to 2033.

North America Breast Cancer Screening Test Market Insights Forecasts to 2033

• The Market Size is Growing at a CAGR of 8.40% from 2023 to 2033
• The North America Breast Cancer Screening Test Market Size is Expected to hold significant share by 2033

The North America Breast Cancer Screening Test Market Size is Anticipated to Hold a Significant Share by 2033, growing at a CAGR of 8.40% from 2023 to 2033.

Market Overview

The market for breast cancer screening tests in North America includes diagnostic instruments and techniques for early breast cancer detection. The North American breast cancer screening tests market, which includes mammography, ultrasound, MRI, and genetic screening methods, is growing due to factors such as rising life expectancy, lifestyle changes, awareness campaigns, improved healthcare accessibility, technological advancements, government initiatives, and healthcare policies. The market is driven by increased awareness of breast cancer, prompting individuals to undergo regular checkups and technological advancements in diagnostic tools. Government initiatives, such as the U.S. Preventive Services Task Force's recommendations for routine mammography screenings for women aged 50 to 74, have increased screening participation. Healthcare policies and insurance coverage reforms in the U.S. and Canada have made screenings more affordable and widespread. Investments in research and development of advanced testing technologies are expected to further drive market growth. As the focus on early detection intensifies, the market for breast cancer screening tests continues to expand.

Report Coverage

This research report categorizes the market for the North America breast cancer screening test market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America breast cancer screening test market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the North America breast cancer screening test market.

Driving Factors

The North American breast cancer screening tests market is driven by rising cases and increased awareness of early diagnosis. Lifestyle changes, environmental factors, and improved life expectancy have led to an epidemic, increasing demand for effective screening techniques. Advances in imaging techniques and genetic testing have improved test accuracy and reliability, making them more accessible to a wider population. Government initiatives and healthcare programs have further made these services affordable for a larger number of women.

Restraining Factors

The market for early breast cancer detection faces challenges due to the high costs of advanced screening technologies, limited healthcare access in rural or economically disadvantaged areas, and fear of safety or pain associated with certain procedures. These challenges, along with occasional skepticism towards new screening methods, may slow the market's growth despite the increasing need for early detection.

Market Segmentation

The North America breast cancer screening test market share is classified into diagnostics test type and end-user.

• The imaging test segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR during the forecast period.

The North America breast cancer screening test market is segmented by diagnostics test type into blood marker test, imaging test, genetic test, and immunohistochemistry test. Among these, the imaging test segment accounted for the largest share in 2023 and is expected to grow at a significant CAGR during the forecast period. Breast cancer detection is primarily achieved through mammography, ultrasound, and MRI, with mammography being the gold standard. These imaging tests have a high adoption rate due to their effectiveness, accessibility, and established clinical use, making them the preferred diagnostic procedure in breast cancer screening.

• The hospitals segment accounted for the highest share in 2023 and is expected to grow at a significant CAGR during the forecast period.

Based on the end-user, the North America breast cancer screening test market is divided into hospitals, diagnostic centres, cancer institutes, and research laboratories. Among these, the hospitals segment accounted for the highest share in 2023 and is expected to grow at a significant CAGR during the forecast period. Most breast cancer screenings are done in hospitals, which provide a wide scope of diagnostic services, such as mammography, ultrasound, and MRI. Hospitals have advanced medical equipment, experienced professionals, and the infrastructure to manage large volumes of patients for routine screenings and follow-up procedures.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America breast cancer screening test market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Agendia BV
• Fujifilm Holdings Corporation
• Hologic Inc.
• Metabolomic Technologies Inc.
• Myriad Genetics
• QIAGEN NV
• Quest Diagnostics Incorporated
• Siemens Healthineers
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In December 2024, the FDA approved Transpara, an AI-based breast imaging program from ScreenPoint Medical, for additional features like temporal comparison and breast density assessment. The goal of these elements is to increase cancer detection rates and improve radiologist performance.

• In August 2024, the IzoView breast computed tomography (CT) imaging device, intended for patients with thick breast tissue, will be introduced, according to plans announced by Izotropic Corporation. Enhancing diagnostic accuracy in difficult circumstances is the goal of this method.

Market Segment

This study forecasts revenue at North America, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the North America breast cancer screening test market based on the below-mentioned segments:

North America Breast Cancer Screening Test Market, By Diagnostics Test Type

• Blood Marker Test
• Imaging Test
• Genetic Test
• Immunohistochemistry Test

North America Breast Cancer Screening Test Market, By End-User

• Hospitals
• Diagnostic Centres
• Cancer Institutes
• Research Laboratories